Clinical Trials Logo

Filter by:
NCT ID: NCT05680480 Recruiting - Lupus Nephritis Clinical Trials

A Study of Telitacicept in Lupus Nephritis

Start date: April 17, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.

NCT ID: NCT05701137 Recruiting - PTSD Clinical Trials

Effectiveness of an EMDR Intervention for Perinatal Loss

Start date: April 17, 2023
Phase: N/A
Study type: Interventional

The investigators objectives is to assess the effectiveness of Eye Movement Desensitization and Reprocessing - recent traumatic episode (EMDR-RTE) as a preventive intervention for Posttraumatic Stress Disorder (PTSD) symptoms after perinatal loss. The hypothesis is that EMDR-RTE treatment may prevent post-traumatic and depressive symptoms in women who suffered perinatal loss.

NCT ID: NCT05707377 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Start date: April 17, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

NCT ID: NCT05707663 Recruiting - Clinical trials for Juvenile-Onset Huntington Disease

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

Start date: April 17, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: - Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? - Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations who are at-risk for HD and who have been diagnosed with HD as adults.

NCT ID: NCT05709197 Recruiting - Pancreatic Cancer Clinical Trials

The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy

REMBRANDT
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial (REMBRANDT) is to evaluate the effectiveness of adding an extra connection (i.e. 'Braun anastomosis') after standard reconstruction in pancreatic head resection in reducing the incidence of delayed gastric emptying.

NCT ID: NCT05711186 Recruiting - Clinical trials for Aortic Valve Stenosis

Structured Shared Decision Making for Patients Undergoing SAVR or TAVR

TOGETHER
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

Transcatheter aortic valve replacement (TAVR) is a well-established alternative to surgical aortic valve replacement (SAVR) for the treatment of patients with severe aortic stenosis regardless of surgical risk. While TAVR and SAVR share some of the benefits and risks, they importantly differ with regards to invasiveness, time to recovery, hemodynamics, as well as options for re-intervention and possibly valve durability. An early benefit of TAVR may be offset by late risks. Therefore, current guidelines of the European Society of Cardiology recommend an integration of patient values and preferences for the selection of the treatment modality. The objective of the TOGETHER trial is to investigate the efficacy of a structured shared decision making approach (SDM) to improve patient-centered outcomes for the choice between SAVR and TAVR. TOGETHER is an investigator-initiated, randomized, open-label, single-center clinical trial. A total of 140 patients referred for treatment of symptomatic severe aortic stenosis and deemed to undergo TAVR or SAVR according to heart team decision will be randomized in a 1:1 ratio to structured SDM or usual care.

NCT ID: NCT05713760 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Start date: April 17, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, Single-Arm, Open-Label, Single Center, Proof of Concept Study to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) on the neck, trunk, or extremities (excluding, axilla, anogenital, and face/scalp).

NCT ID: NCT05724797 Recruiting - Healthy Volunteers Clinical Trials

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age, inclusive.

NCT ID: NCT05746611 Recruiting - Clinical trials for Latent Tuberculosis Infection

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Start date: April 17, 2023
Phase: Phase 4
Study type: Interventional

Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only

NCT ID: NCT05753618 Recruiting - Clinical trials for Early-stage Breast Cancer

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

REaCT-OGF
Start date: April 17, 2023
Phase: Phase 4
Study type: Interventional

The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.